Drug
FX006 clinical trials
Also written FX006.
- studies test it
- 17
- open now
- 0
- in phase 3
- 5
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
17 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 12
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 2
Pacira Pharmaceuticals, Inc (15) · Northwell Health (1) · The University of Texas Health Science Center, Houston (1)
Studies
Open first, then newest update. How each study uses FX006 is read from its arms, and is right about nine times in ten.
Testing it · 17
- Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff DiseaseActive, not recruitingPhase 3Northwell HealthNCT04094298Written as FX006 Injection
- Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the HipCompletedPhase 2Pacira Pharmaceuticals, IncNCT04065074Written as FX006 32 mg
- Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or HipCompletedPhase 2Pacira Pharmaceuticals, IncNCT03382262Written as FX006 32 mg
- Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OACompletedPhase 2Pacira Pharmaceuticals, IncNCT03378076Written as FX006 32 mg
- Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02003365Written as FX006 10 mg
- Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02116972Written as FX006 32 mg
- Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT03046446Written as FX006 32 mg
- Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02637323Written as FX006 32 mg
- Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT02357459Written as FX006
- Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 DiabetesCompletedPhase 2Pacira Pharmaceuticals, IncNCT02762370Written as FX006 32 mg
- Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT01487200Written as FX006 10 mg
- Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT03529942Written as FX006 32 mg
- Study of FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT01487161Written as FX006
- Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive CapsulitisTerminatedPhase 2Pacira Pharmaceuticals, IncNCT04160091Written as FX006
- Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip OsteoarthritisTerminatedPhase 3Pacira Pharmaceuticals, IncNCT03793010Written as FX006
- Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the KneeTerminatedPhase 2Pacira Pharmaceuticals, IncNCT02468583Written as FX006 32 mg
- Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric BursitisCompletedPhase 2The University of Texas Health Science Center, HoustonNCT04182672Written as FX006
Codes
What other systems call FX006 · ClinicalTrials.gg INT001115
- MeSH (NLM) C000631825FX006One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631825 | FX006 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.